Research Spotlight

Down syndrome brain and Alzheimer's disease

Research Spotlight Community Spotlight

Statement on accelerated approval of Leqembi to treat mild-stage Alzheimer’s disease in the general population

On Friday, January 6, the U.S. Food & Drug Administration (FDA) granted accelerated approval for…

Kate O’NeillJanuary 10, 2023

Our Impact Report 2022 highlights our accomplishments as an organization during a remarkable year. 2022 saw Down syndrome research receive unprecedented attention from policymakers, the media, and the pharmaceutical and life sciences industries. Click here to read our full report!

https://lumindidsc.org/wp-content/uploads/2023/01/Impact_Report_2022_FINAL_Digital.pdf

Research News Research Spotlight

New steps forward in treating Alzheimer’s disease with lecanemab: Clinical trial reveals clear efficacy in removing brain plaque

At an Alzheimer’s disease research conference last week, new clinical trial data was presented for…

Kate O’NeillDecember 5, 2022

Press Release Research Spotlight

DS-CTN Data and Safety Monitoring Board (DSMB)

LuMind IDSC and the Down Syndrome Clinical Trials Network are pleased to announce the launch…

Kate O’NeillNovember 16, 2022

Research Spotlight

Lecanemab: New Treatment for Alzheimer’s Disease

Eisai, a Japanese pharmaceutical company, and its partner Biogen, a Massachusetts-based biotechnology company, recently announced…

Kate O’NeillNovember 1, 2022

Long-COVID and its impact on cognitive function in adults with intellectual disability

Research Spotlight

NTG Publishes Advisory on Long-COVID in Adults with Intellectual Disability

In a recent report, the National Task Group on Intellectual Disabilities and Dementia Practices (NTG)…

Kate O’NeillOctober 17, 2022

Community Spotlight Research Spotlight

Why is Down syndrome research important?

Learn more about Down syndrome research Learn more about resources for families Learn more about…

Kate O’NeillOctober 3, 2022

Research Spotlight

Potential New Therapy for Adults with Down Syndrome

September 16, 2022 Research recently published in the journal Science (Manfredi-Lozano et al., Science 377,…

Kate O’NeillSeptember 16, 2022

LIFE-DSR Down Syndrome Research Study with John Cronin

Community Spotlight Research Spotlight

LIFE-DSR: up close and personal with John

In July 2022, John Cronin and his parents invited LuMind IDSC to follow their family…

Kate O’NeillSeptember 7, 2022

Research Spotlight

A Closer Look at the CMS Decision on Aduhelm and Anti-Amyloid Drugs

AN EXPLAINER FOR THE DOWN SYNDROME COMMUNITY April 15, 2022 BACKGROUND On April 7,…

CapetivateApril 19, 2022

Statement on accelerated approval of Leqembi to treat mild-stage Alzheimer’s disease in the general population

Our Impact Report 2022 highlights our accomplishments as an organization during a remarkable year. 2022 saw Down syndrome research receive unprecedented attention from policymakers, the media, and the pharmaceutical and life sciences industries. Click here to read our full report!

New steps forward in treating Alzheimer’s disease with lecanemab: Clinical trial reveals clear efficacy in removing brain plaque

DS-CTN Data and Safety Monitoring Board (DSMB)

Lecanemab: New Treatment for Alzheimer’s Disease

NTG Publishes Advisory on Long-COVID in Adults with Intellectual Disability

Why is Down syndrome research important?

Potential New Therapy for Adults with Down Syndrome

LIFE-DSR: up close and personal with John

A Closer Look at the CMS Decision on Aduhelm and Anti-Amyloid Drugs

Recent Posts

CONTACT LUMIND IDSC

QUICK LINKS

NEED MORE INFORMATION?